Cesamet Launch Will Highlight Longer Duration of Action Vs. Marinol
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant will also study the cannabinoid-receptor agonist in combination with other anti-emetics.
You may also be interested in...
GW Licenses U.S. Sativex Rights To Otsuka In $273 Million Deal
Firms plan to enter a longer-term collaboration later this year to discover novel cannabinoids for use in pain and central nervous system disorders.
GW Licenses U.S. Sativex Rights To Otsuka In $273 Million Deal
Firms plan to enter a longer-term collaboration later this year to discover novel cannabinoids for use in pain and central nervous system disorders.
Valeant Plans New Sales Strategy For Cesamet; Ends Deal With Par
The two parties have terminated a marketing agreement for the anti-emetic based on a change in strategic priorities.